
|Articles|February 3, 2005
FDA approves gene-based test for bladder cancer
Abbott's UroVysion DNA probe assay has been approved by the FDA for use as an aid in initial diagnosis of bladder cancer in patients with hematuria and suspected of having bladder cancer.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
NDV-01 produces robust 9-month results in high-risk NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5


















